DAFTAR PUSTAKA
1. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and Melasma. J Cosmet Dermatol 2007;6:195-202.
2. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, Tretinoin 0,05%, Fluocinolone Acetonide 0,01%: A Safe and Efficacious 12-Month Treatment for Melasma. Therapeutic for the Clinician, Cutis 2005;75:57-62.
3. Bauman L. Disorder of Pigmentation. Dalam: Cosmetic Dermatology Principles and Practice. Hongkong: McGraw-Hill Company, 2002.h.63-7.
4. Grimes PE. Melasma: Etiologic and Therapeutic Considerations. Arch Dermatol 1995;131:1453-57.
5. Victor FC, Gelber J, Rao B. Melasma: A Review. J Cutan Med and Surg 2004;8(2):97-102.
6. Chan R, et al. A Randomized Controlled Trial of the Efficacy and Safety of Fixed Triple Combination (Fluocinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05%) Compared with Hydroquinone 4% Cream in Asian Patient with Moderate to Severe Melasma. Br J Dermatol 2008;159:697-703.
7. Menter A. Rational for the Use of Topical Coticosteroids in Melasma. J Drugs Dermatol 2004; 3(2):169-174.
8. Lapeere H, et al. Hypomelanoses and Hypermelanoses. Dalam: Fitzpatrick's Dermatology in General Medicine (Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ),Vol. 1. Edisi ke-7. New York: McGraw-Hill; 2008.h.622-40.
9. Rekam Medik Bagian Ilmu Kesehatan Kulit dan Kelamin RSUP. H. Adam Malik Medan Tahun 2009.
10. Tork HM. A Comprehensive Review of the Long-Term and Short-Term Treatment of Melasma with a Triple Combination Cream. Am J Clin Dermatol 2006;7(4):223-30.
11. Cestari T, Adjadji L, Hux M, Shimizu MR, Rives VP. Cost-Effectiveness of a Fixed Combination of Hidroquinone/Tretinoin/Fluocinolone Cream Compared with Hidroquinone Alone in the Treatment of Melasma. J Drugs Dermatol 2007;6(2):153-60.
12. Katsambas A, Stefanaki C. Disorders of Pigmentation: Unapproved Treatments. Clinics in Dermatology 2002;20:649-59.
13. Balkrishnan, et al. Development and Validation of a Health-Related Quality of Life Instrument for Women with Melasma. Br J Dermatol 2003;149:572-77.
14. Moertolo. Pengaruh Astaxanthin (3,3’-dihydroxy-β, β’-carotene-4, 4’-dione) Topikal dan Sistemik terhadap Melasma Tipe Epidermal. Makalah Simposium The Natural Astaxanthin Symposium 2009: An Update on Clinic Research. 2009:1-14.
15. Scherdin U, et al. Skin-Lightening Effect of a New Face Care Product in Patients with Melasma. J Cosmet Dermatol 2008;7:68-75.
16. Cestari TF, Hassun K, Sittart A, Viegas MdL. A Comparison of Triple Combination Cream and Hydroquinone 4% Cream for the Treatment of Moderate to Severe Facial Melasma. J Cosmet Dermatol 2007;6:36-9.
17. Tirado-Sanchez A, Santamaria-Roman A, Ponce-Olivera RM. Efficacy of Dioic Acid Compared with Hydroquinone in the Treatment of Melasma. Int J Dermatol 2009;48:893-5.
18. Maeda K, Naganuma M, Fukuda M, Matsunaga J, Tomita Y. Effect of Pituitary and Ovarian Hormones on Human Melanocytes In Vitro. Pigment Cell Res 1996;9:204-12.
19. Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic Acid as a New Therapeutic Peeling Agent in Melasma. Dermatol Surg 2005;31:149-54.
20. Rikyanto. Profil Kasus Melasma Pelanggan Klinik Kosmedik di RSUD Kota Yogyakarta. Media Dermato Venerologi Indonesia 2006;33(1).
21. Shudarmono A, Febrianti A, Rata I, Bernadette I. Epidemiologi Melasma di Poliklinik Departemen Ilmu Kesehatan Kulit dan Kelamin RS. Dr. Cipto Mangunkusumo Tahun 2004. Media Dermato Venereologi Indonesia 2006;33(1).
22. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of Melasma. J Am Acad Dermatol;54(5):S272-81.
23. Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of Facial Hyperpigmentation. Am J Clin Dermatol 2000;1(5):261-8.
24. Pandya AG,et al. Reliability Assessment and Validation of the Melasma Area and Severity Index (MASI) and a New Modified MASI Scoring Method. J Am Acad Dermatol 2010:1-8.
25. Gulzar K, Mujtaba G, Hameed S. Comparison between Efficacy of Serial Glycolic Acid Peel and Triple Combination Cream vs. Triple Combination Cream Alone in Treatment Melasma. J Pak Assoc Dermatol 2010;20:84-8.
26. Huh SY, Shin J, Na J, Huh C, Youn S. The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-Face Trial. Ann Dermatol 2010; 22(1):21-5.
27. Cholis M. Patogenesis Melasma. Majalah Kedokteran Indonesia Jakarta, 1995;45(10): 582-7. 28. Jimbow K, Minamitsuji Y. Topical Therapies for Melasma and Disorders of Hyperpigmentation.
Dermatologic Therapy 2001;14:35-45.
29. Park HY, Pongpudpunth M, Lee J, Yaar M. Biology of Melanocytes. Dalam: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Palter AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine; edisi ke-7. New York: McGraw-Hill; 2008:591-608.
30. Koesoema L. Faktor-faktor yang Berhubungan dengan Terjadinya Melasma pada Pekerja Perempuan di Perkebunan Tebu PTPN II Klumpang. Tesis. Medan: Universitas Sumatera Utara, 2009.
31. Damayanti N, Listiawan MY. Fisiologi dan Biokomia Pigmentasi Kulit. Berkala Ilmu Penyakit Kulit dan Kelamin 2004;16(2): 156-62.
32. Kang WH,et al. Melasma: Histopathological Characteristic in 56 Korean Patients. Br J Dermatol 2002;146:228-37.
34. Nasution D. Kelainan Hiperpigmentasi dan Melasma. Disampaikan dalam Symposium Kelainan Pigmentasi Kulit dan Penanggulangannya. PERDOSKI, Jakarta 6 Januari1998.
35. Lawrence N, Cox SE, Brody HJ. Treatment of Melasma with Jessner’s Solution versus Glycolic Acid: A Comparison of Clinical Efficacy and Evaluation of the Predictive Ability of Wood’s Light Examination. J Am Acad Dermatol 1997; 36(4):589-93.
36. Pirma Siburian. The Role of Astaxanthin for An Aging and Related Diseases. Makalah
Simposium The Natural Astaxanthin Symposium 2009: An Update on Clinic Research, 2009:1-9. 37. Pandya A, Bemeburg M, Ortonne JP, Picardo§ M. Guidelines for Clinical Trials in Melasma. Br J
Dermatol 2007; 156(suppl 1):2-28.
38. Tjokroprawiro A, Lea Y. Astaxanthin, The Only Strongest and Safest Antioxidant without Any Pro-Oxydant. Disampaikan dalam Symposium PERKENI, Surabaya 25 Agustus 2002.
39. Guerin M, Huntley ME, Olaizola M. Haematococcus Astaxanthin: Application for Human Health and Nutrition. TRENDS in Biotechnology 2003; 21(5):210-16.
40. Hexsel D, Rendon M, Arelano I. Ethnic Considerations in the Treatment of Hispanic and Latin-American Patient with Hyperpigmentation. Br J Dermatol 2007;156(suppl. 1):7-12.
41. Zawar VP, Mhaskar ST. Exogenous Ochronosis Following Hydroquinone for Melasma. J Cosmet Dermatol 2004;3:234-6.
42. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmentation Agents: An Update Review on Biological, Chemical and Clinical Aspect. Pigment Cell Res 2006;19:550-71.
43. Sambandan DR, Ratner D. Sunscreens: An Overview and Update. J Am Acad Dermatol 2010;1-8 44. Kim SM, Oh BH, Lee YW, Choe YB, Ahn KJ. The Relation between the Amount of Sunscreen
Applied and the Sun Protection Factor in Asian Skin. J Am Acad Dermatol;62(2):218-22. 45. Rosen CF. Topical and Systemic Photoprotection. Dermatologic Therapy 2003;16:8-15.
47. Taylor S, Westerhof W, Im S, Lim J. Noninvasive Techniques for Evaluation of Skin Color. J Am Acad Dermatol 2006;54(5):S282-90.
48. Bhor U, Pande S. Scoring System in Dermatology. Indian J Dermatol Venereol Leprol 2006;72(4):315-20.
49. Hurley ME, Guevara IL, Gonzales RM, Pandya GA. Efficacy of Glycolyc Acid Peels in the Treatment of Melasma. Arch Dermatology 2002; 138:1578-82.
50. Setyaningsih KLS. Prevalensi melasma dan Pengaruh Pajanan Sinar Matahari terhadap timbulnya Melasma pada Polisi Wanita di Wilayah Polda Metro Jaya, Tesis. Jakarta : Universitas Indonesia, 1997.
